RxDoctor Payments Data

Sheri Graboyes

Adult Health · Boynton Beach, FLNPI 1831601608

Payments from drug & device makers

$10,502in general payments, 2019–2025

Across 358 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Cvrx, Inc.$1K
  • Amgen$1K
  • Boehringer Ingelheim$750
  • Johnson & Johnson$570
  • AstraZeneca$533
  • plus $4K from 25 others

What the payments were for

  • Travel & lodging$1,84018%
  • Food & beverage$8,61782%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,502 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$46,172
Medicare patients
306
Services billed
573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$114,150
JardianceEmpagliflozin52$39,721
XareltoRivaroxaban44$39,063
EntrestoSacubitril/Valsartan18$26,149
Repatha SureclickEvolocumab23$18,329
NexlizetBempedoic Acid/Ezetimibe17$6,851
Rosuvastatin Calcium156$2,653
Metoprolol Succinate197$1,752
Olmesartan Medoxomil36$1,628
Prasugrel Hcl11$1,215
Eplerenone15$990
Valsartan70$958
Ranolazine ErRanolazine11$844
Carvedilol115$767
Nebivolol Hcl13$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$322$114,150114 claims
Boehringer IngelheimJardiance$750$39,72152 claims
Johnson & JohnsonXarelto$570$39,06344 claims
NovartisEntresto$467$26,14918 claims
Esperion Therapeutics, Inc.Nexlizet$197$6,85117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →